Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.

 

Important Public Notice: ANCC Magnet Recognition Program® - Site Visit through November 4, 2022. Click here to learn more.

MENU

Dr. Iberia Romina Sosa Appointed New Chief of the Division of Hematology at Fox Chase Cancer Center

January 31, 2022

Dr. Iberia Romina Sosa appointed chief of the Division of Hematology in the Department of Hematology/OncologyDr. Iberia Romina Sosa appointed chief of the Division of Hematology in the Department of Hematology/Oncology

PHILADELPHIA (January 31, 2022)—Iberia Romina Sosa, MD, PhD, an associate professor at Fox Chase Cancer Center, was recently appointed the new chief of the Division of Hematology in the Department of Hematology/Oncology.

“I feel truly privileged to have been offered this role and to have the opportunity to work with such a talented group of faculty and staff in our hematology section,” said Sosa.

“This appointment is a testimony to the skills that Dr. Sosa has and the hard work that she has put in over the last several years at Fox Chase. Dr. Sosa has been a leader in both our clinical and research efforts in benign and malignant hematology,” said Martin J. Edelman, MD, chair of the Department of Hematology/Oncology.

As a physician, Sosa’s treatment focus is on consultative hematology, specifically myeloproliferative disorders, bleeding/thrombosis, and bone marrow failure. As chief of the Division of Hematology, Sosa’s focus will be on making sure that the division is meeting the clinical needs of the cancer center and contributing to the advancement of research and innovation.

“I look forward to growing our research portfolio by bringing exciting new studies that will meet the evolving clinical needs of our patients, as well as innovating new projects with our research colleagues in the cancer center,” said Sosa.

The Division of Hematology covers many different diseases including benign, myeloid, and lymphoid processes. Sosa said that a need for the division’s services continues to increase both within the Temple University Health System, which Fox Chase is part of, and neighboring private practice communities. “I hope to continue to recruit talented faculty to meet the growing clinical need and to continue to deliver excellent care to our patients.”

Sosa is an associate member of the American Society of Clinical Oncology, the American Society of Hematology, and the Hemostasis and Thrombosis Research Society.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Connect with Fox Chase